Patrick J. Christmas Sells 15,000 Shares of Regenxbio Inc (RGNX) Stock
Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $72.06, for a total value of $1,080,900.00. Following the transaction, the senior vice president now owns 2,669 shares in the company, valued at approximately $192,328.14. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
RGNX stock opened at $66.37 on Friday. Regenxbio Inc has a fifty-two week low of $23.25 and a fifty-two week high of $85.10. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -27.09, a PEG ratio of 14.80 and a beta of -0.49.
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a return on equity of 27.33% and a net margin of 44.30%. The firm had revenue of $5.31 million for the quarter. As a group, sell-side analysts expect that Regenxbio Inc will post 1.64 earnings per share for the current fiscal year.
A number of research analysts have weighed in on the company. ValuEngine downgraded Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Raymond James reiterated a “buy” rating on shares of Regenxbio in a report on Monday, October 29th. Barclays upped their target price on Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Chardan Capital upped their target price on Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 16th. Finally, BidaskClub downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $84.07.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Article: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.